Drug recall · March 13, 2024
Mercaptopurine Tablets recall
Why: Failed Dissolution Specifications: results slightly under spec at at 9-months.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Mercaptopurine Tablets, USP 50 mg, packaged in: a) 25-count bottle (NDC 69076-913-02), b) 250-count bottle (NDC 69076-913-25), Rx only, Manufactured for: Quinn Pharmaceuticals, Boca Raton, FL, www.quinnrx.com
- Lots / codes
Lot #: a)22K012, 22K013A, Exp: 04/30/2024; 23A001, 23A002A, Exp: 07/31/2024; 23D006, 23D007A, 23D007C, Exp:10/31/2024; b)22K013B, Exp: 04/30/2024; 23A002B, Exp:07/31/2024; 23D007B, Exp: 10/31/2024.
- Quantity
- 54, 131 bottles
- Company
- Stason Pharmaceuticals, Inc., Irvine, CA
- Distribution
- USA Nationwide
- Initiated
- February 9, 2024 · Voluntary: Firm initiated
- Classified
- March 6, 2024
- Reported
- March 13, 2024
- Ended
- February 5, 2026
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Mercaptopurine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.